GB2467491A - Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies - Google Patents

Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies Download PDF

Info

Publication number
GB2467491A
GB2467491A GB1009145A GB201009145A GB2467491A GB 2467491 A GB2467491 A GB 2467491A GB 1009145 A GB1009145 A GB 1009145A GB 201009145 A GB201009145 A GB 201009145A GB 2467491 A GB2467491 A GB 2467491A
Authority
GB
United Kingdom
Prior art keywords
encephalitis virus
equine encephalitis
recombinant antibodies
venezuelan equine
humanized anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1009145A
Other versions
GB201009145D0 (en
GB2467491B (en
GB2467491C (en
GB2467491A8 (en
Inventor
Wei-Gang Hu
Leslie P Nagata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CA MINISTER ENERGY
Minister of National Defence of Canada
Original Assignee
CA MINISTER ENERGY
Minister of National Defence of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CA MINISTER ENERGY, Minister of National Defence of Canada filed Critical CA MINISTER ENERGY
Publication of GB201009145D0 publication Critical patent/GB201009145D0/en
Publication of GB2467491A publication Critical patent/GB2467491A/en
Publication of GB2467491A8 publication Critical patent/GB2467491A8/en
Publication of GB2467491B publication Critical patent/GB2467491B/en
Application granted granted Critical
Publication of GB2467491C publication Critical patent/GB2467491C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A CDR grafted humanized recombinant antibody against infection from Venezuelan equine encephalitis virus (VEEV) comprises a human Ig framework having CDRs from murine mAb 1A4A1 VH and VL. DNA sequences, expression vectors incorporating such sequences and transformed host cells are also provided. Also provided are pharmaceutical compositions and methods of prophylaxis and treatment against VEEV infection using the humanized recombinant antibodies of the invention.
GB201009145A 2007-11-01 2008-11-03 Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies Expired - Fee Related GB2467491C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002607771A CA2607771A1 (en) 2007-11-01 2007-11-01 Humanized anti-venezuelan equine encephalitis virus recombinant antibody
PCT/CA2008/001940 WO2009055936A1 (en) 2007-11-01 2008-11-03 Humanized anti-venezuelan equine encephalitis virus recombinant antibodies

Publications (5)

Publication Number Publication Date
GB201009145D0 GB201009145D0 (en) 2010-07-14
GB2467491A true GB2467491A (en) 2010-08-04
GB2467491A8 GB2467491A8 (en) 2010-12-22
GB2467491B GB2467491B (en) 2013-03-20
GB2467491C GB2467491C (en) 2013-03-27

Family

ID=40589892

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201009145A Expired - Fee Related GB2467491C (en) 2007-11-01 2008-11-03 Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies

Country Status (3)

Country Link
CA (2) CA2607771A1 (en)
GB (1) GB2467491C (en)
WO (1) WO2009055936A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501157B2 (en) 2007-11-01 2013-08-06 Her Majesty the Queen in right of Canada as represented by The Ministry of National Defence Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies
GB0916630D0 (en) * 2009-09-22 2009-11-04 Secr Defence Antibody
JP6126532B2 (en) 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-IL-23 antibody
MX368653B (en) 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anti-il-23p19 antibodies.
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
TWI711629B (en) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 Compound targeting il-23a and tnf-alpha and uses thereof
CN107849150B (en) 2015-06-24 2021-12-14 Jcr制药股份有限公司 Fusion proteins comprising BDNF
CN114409783A (en) * 2015-06-24 2022-04-29 Jcr制药股份有限公司 Anti-human transferrin receptor antibodies across the blood brain barrier
CN107586335B (en) * 2016-07-06 2020-12-29 中国科学院微生物研究所 Humanized monoclonal antibody and application
JP6956741B2 (en) 2016-12-26 2021-11-02 Ｊｃｒファーマ株式会社 A novel anti-human transferrin receptor antibody that crosses the blood-brain barrier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANG, J, et al.: 'Stable antibody expression at therapeutic levels using the 2A peptide.' NATURE BIOTECHNOLOGY, Vol. 23, No. 5, May 2005, pages 584 - 590 *
HU, W-G, et al.: 'Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus.' VACCINE. Vol. 25, No. 16, April 2007, pages 3210 - 3214 *

Also Published As

Publication number Publication date
CA2607771A1 (en) 2009-05-01
GB201009145D0 (en) 2010-07-14
GB2467491B (en) 2013-03-20
WO2009055936A1 (en) 2009-05-07
CA2704119A1 (en) 2009-05-07
CA2704119C (en) 2014-12-30
GB2467491C (en) 2013-03-27
GB2467491A8 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
GB2467491A (en) Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies
CN116096412A (en) Compounds specific for coronavirus S proteins and uses thereof
CN107532188B (en) CD20 binding molecules and uses thereof
TWI682938B (en) Method for changing antibody isoelectric point by replacing amino acids in CDR region
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
CA3053360A1 (en) Anti-lag3 antibodies
WO2008063771A3 (en) Anti-cd20 antibodies and methods of use
AR105026A1 (en) ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FcRH5 AND METHODS FOR USE
JP2016536020A5 (en)
SG151284A1 (en) Antibodies against ccr5 and uses thereof
EA202091590A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS
CN104364265A (en) Anti-FCRN antibodies
WO2008137915A3 (en) Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
TW201420600A (en) Anti-mesothelin binding proteins
WO2008055206A3 (en) Humanized anti-factor d antibodies
RU2013125459A (en) ANTIBODIES AGAINST c-Met RECEPTOR PROTEIN
WO2019196309A1 (en) Anti-pd-l1 antibody and use thereof
R Strohl Antibody discovery: sourcing of monoclonal antibody variable domains
WO2009001840A1 (en) Anti-prominin-1 antibody having adcc activity or cdc activity
RU2008138541A (en) METHODS OF DESTRUCTION OF CELLS USING ANTI-EPHA4 ANTIBODIES EFFECTIVE FUNCTIONS
RU2018106456A (en) ANTIBODY TO EPHA4
WO2020232427A3 (en) Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins
IL250289B2 (en) Angiopoietin-like 4 antibodies and methods of use
US20200347137A1 (en) Bispecific antibodies and methods of making and using thereof
MX2021004897A (en) Human pd-l1 antibodies.

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20191103